IL10 and COVID-19: As stated earlier, MSC-based therapy may contribute to a reduction in the levels of pro-inflammatory cytokines and chemokines in COVID-19 by responding to the hyperinflammatory microenvironment through the release of paracrine/immunomodulatory factors, including transforming growth factor-β, hepatocyte growth factor, indoleamine 2,3-dioxygenase, and IL-10 [36, 66].